Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2023/01/01 by Bruce Strober, Diamant Thaçi, Howard Sofen +13 · 1 citation

paper · doi:10.1016/j.jaad.2022.08.061

Cited by

• Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management